Droncit

Droncit Manufacturers

• Bayer Healthcare Llc Animal Health Division
  

  ×

  Droncit | Bayer Healthcare Llc Animal Health Division

  

  ---

  Droncit (praziquantel) Injectable Cestocide may be administered by either the subcutaneous or intramuscular route to dogs and cats. The recommended dosage of praziquantel varies according to body weight. Smaller animals require a relatively larger dosage. The optimum dosage for each individual animal will be achieved by utilizing the following dosage schedule.

  DOGS AND PUPPIES†

  Dogs:

  5 lbs. and under      0.3 mL

  6-10 lbs.                  0.5 mL

  11-25 lbs.                1.0 mL

  over 25 lbs.             0.2 mL /5 lbs.
                                  body weight to a
                                  maximum of 3 mL

  † Not intended for use in puppies less than four (4) weeks of age.

  CATS AND KITTENS††

  Cats:

  Under 5 lbs.            0.2 mL

  5-10 lbs.                  0.4 mL

  11 lbs. and over      0.6 mL maximum

  †† Not intended for use in kittens less than six (6) weeks of age.

  FASTING:

  The recommended dosage of praziquantel is not affected by the presence or absence of food in the gastrointestinal tract, therefore, FASTING IS NEITHER NECESSARY NOR RECOMMENDED.

  ADMINISTRATION:

  Droncit (praziquantel) Injectable Cestocide may be administered by either the subcutaneous or intramuscular route to dogs and cats. The intramuscular route may be preferred in dogs due to a brief period of pain that occasionally follows subcutaneous administration. Anaphylactoid reactions were not observed in clinical trials. However, as with any drug an anaphylactoid reaction can occur with this product and should be treated symptomatically if it occurs.

  RETREATMENT:

  For those animals living where reinfections are likely to occur, clients should be instructed in the steps to optimize prevention, otherwise, retreatment may be necessary. This is true in cases of Dipylidium caninum where reinfection is almost certain to occur if fleas are not removed from the animal and its environment. In addition, for control of Echinococcus multilocularis, a program of regular treatment every 21 to 26 days may be indicated (see E. multilocularis section below).

  ECHINOCOCCUS MULTILOCULARIS:

  Echinococcus multilocularisis a tapeworm species ordinarily considered to be found in wild canids, including foxes, coyotes and wolves. The parasite has also been identified in domestic dogs and cats and potentially is a serious public health concern by involving humans as accidental intermediate hosts.

  The life cycle of the parasite is based on a predator-prey relationship, as depicted above.

  The adult tapeworm is small (1-4mm) and resides in the intestinal tract of the definitive host (wild or domestic canids). Eggs from the adult tapeworm are shed in the feces of the infected canid. Rodents such as mice and voles serve as the intermediate host for E. multilocularis. Eggs ingested by rodents develop in the liver, lungs and other organs to form multilocular cysts. The life cycle is completed after a canid consumes a rodent infected with cysts. After ingestion of the infected rodent, larvae within the cyst develop to adult tapeworms in the intestinal tract of the canid. Eggs may begin to be passed in the feces of the canid approximately 28 days later.

  This parasite poses a serious public health problem because of the possibility for human involvement in the life cycle. If eggs shed by an infected canid are accidentally ingested, a highly pathogenic condition (Alveolar Hydatid Disease) results from development of the cyst stage in humans.

  The original geographic distribution of E. multilocularis was primarily confined to northern areas of North America. Current evidence indicates migration of the parasite well into the continental United States.2,3

  Domestic dogs living in E. multilocularis endemic areas that roam freely with the opportunity to catch wild rodents are at risk for infection. Pet owners should be advised on how to minimize this risk. Proper restraint of roaming dogs should be encouraged, along with regular treatment with Droncit Injectable solution, following the dosing schedule aforementioned and precautions indicated below.

  Additional information on the life cycle and epidemiology of this parasite is available in veterinary parasitology texts.4,5

  Diagnosis:

  Diagnosis of E. multilocularis in canids is difficult. The adult tapeworm produces no clinical signs of infection. Tapeworm segments (proglottids) are usually not observed in the feces. E. multilocularis eggs, observed using microscopic fecal examination procedures, are similar in appearance to the common taeniid species of canids such as Taenia pisiformis.

  Assistance in the diagnosis of E. multilocularis may be available from a state veterinary diagnostic laboratory. Additional information regarding areas where E. multilocularis is suspected or has been confirmed may be obtained from area veterinary schools or the Centers for Disease Control in Atlanta, GA.

  Treatment:

  Dogs infected with E. multilocularis should be treated to prevent exposure of humans to infective eggs and to reduce perpetuation of the parasite's life cycle.

  The dosage of Droncit Injectable solution for removal of E. multilocularis is the same as that indicated for the removal of the other tapeworm species listed on the label. Laboratory efficacy studies have demonstrated the recommended dosage is 100% efficacious for removal of this tapeworm.

  Under condition of continual exposure to wild rodents, retreatment of the dog at 21-26 day intervals is recommended to prevent the shedding of infectious eggs.

  Close
  No Recall

  More Info